CSM
PRTK

Central Square Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Central Square Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,583
Closed -$59K – 44
2014
Q1 		$59K Hold
1,583
– – 0.06% 38
2013
Q4 		$64K Buy
+1,583
New +$67.2K 0.05% 47

Other funds holding PRTK

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Central Square Management's PRTK Position: Q2 2014 in Review

Central Square Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2014, closing a stake of 1,583 shares — an estimated $59K sold.

Central Square Management first reported a position in PRTK in Q4 2013 and held it in 2 quarters. The position peaked at $64K in Q4 2013. 36 funds tracked by Wall St. Rank hold PRTK as of Q2 2014.

  • Central Square Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Central Square Management sold 1,583 Paratek Pharmaceuticals, Inc. shares in Q2 2014, an estimated $59K.
  • Central Square Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2013 and held it in 2 quarters.
  • Central Square Management's Paratek Pharmaceuticals, Inc. position peaked at $64K in Q4 2013.
  • 36 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2014.

Based on Central Square Management's 13F filing for Q2 2014, filed 8 Aug 2014.